Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc. - ROEverified

YMAB

Price:

$8.61

Market Cap:

$391.22M

Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a monoclonal antibody administered alongside granulocyte-macrophage colony-stimulating factor, targeting high-risk neuroblastoma in children when the disease has returned or proven resistant to prior treatments. Beyond its approved indication, DANYELZA is undergoing Phase II trials for new applications, including initial and third-line neuroblastoma, as well as relapsed osteosarcoma. Furthermore, Y-mAbs is progressing with a GD...[Read more]

Industry

Biotechnology

IPO Date

2018-09-21

Stock Exchange

NASDAQ

Ticker

YMAB

The ROE as of June 2026 (TTM) for Y-mAbs Therapeutics, Inc. (YMAB) is -16.98%

According to Y-mAbs Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -16.98%. This represents a change of 177.70% compared to the average of -6.12% of the last 4 quarters.

Y-mAbs Therapeutics, Inc. (YMAB) Historical ROE (quarterly & annually)

How has YMAB ROE performed in the past?

The mean historical ROE of Y-mAbs Therapeutics, Inc. over the last ten years is -57.73%. The current -16.98% ROE has changed -70.59% with respect to the historical average. Over the past ten years (40 quarters), YMAB's ROE was at its highest in in the March 2021 quarter at 13.25%. The ROE was at its lowest in in the June 2022 quarter at -32.21%.

Quarterly (TTM)
Annual

Average

-57.73%

Median

-32.24%

Minimum

-141.42%

Maximum

-21.22%

Y-mAbs Therapeutics, Inc. (YMAB) ROE by Quarter and Year

Discovering the peaks and valleys of Y-mAbs Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 185.11%

Maximum Annual ROE = -21.22%

Minimum Annual Increase = -83.51%

Minimum Annual ROE = -141.42%

Quarterly (TTM)
Annual
YearROEChange
2024-32.24%51.97%
2023-21.22%-75.75%
2022-87.50%185.11%
2021-30.69%-72.78%
2020-112.76%184.30%
2019-39.66%28.79%
2018-30.79%32.03%
2017-23.32%-83.51%

Y-mAbs Therapeutics, Inc. (YMAB) Average ROE

How has YMAB ROE performed in the past?

The current ROE of Y-mAbs Therapeutics, Inc. (YMAB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-46.99%

5-year avg

-56.88%

10-year avg

-57.73%

Y-mAbs Therapeutics, Inc. (YMAB) ROE vs. Peers

How is YMAB’s ROE compared to its peers?

Y-mAbs Therapeutics, Inc.’s ROE is greater than G1 Therapeutics, Inc. (-92.13%), less than Revance Therapeutics, Inc. (466.15%), greater than Orchard Therapeutics plc (-5.12%), greater than Vigil Neuroscience, Inc. (-122.87%), greater than Checkpoint Therapeutics, Inc. (-2185.94%), greater than Climb Bio, Inc. (-31.46%), greater than iTeos Therapeutics, Inc. (-28.60%), greater than Sinovac Biotech Ltd. (-1.13%), greater than Big Cypress Acquisition Corp. (-0.29%), greater than SomaLogic, Inc. (-18.59%),

Build a custom stock screener for Y-mAbs Therapeutics, Inc. (YMAB) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Y-mAbs Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Y-mAbs Therapeutics, Inc. (YMAB) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Y-mAbs Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Y-mAbs Therapeutics, Inc.'s ROE?

How is the ROE calculated for Y-mAbs Therapeutics, Inc. (YMAB)?

What is the highest ROE for Y-mAbs Therapeutics, Inc. (YMAB)?

What is the 3-year average ROE for Y-mAbs Therapeutics, Inc. (YMAB)?

What is the 5-year average ROE for Y-mAbs Therapeutics, Inc. (YMAB)?

How does the current ROE for Y-mAbs Therapeutics, Inc. (YMAB) compare to its historical average?